T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with XXXX .

@entity1 @entity1261 @entity742 @entity43256 @entity3118 @entity281 @entity2132 @entity348 @entity1583
We report a prospective phase II clinical trial in 35 adult @entity1 (median age 40.5 years) with @entity1583 who received T cell-depleted, hematopoietic stem cell transplants from HLA-compatible, unrelated donors. The cytoreductive regimen consisted of hyperfractionated @entity348 , thiotepa, and @entity3118 . The preferred graft source was @entity1261 ( @entity1261 )-mobilized peripheral blood stem cells (PBSC). PBSC were @entity43256 (+) selected, followed by @entity742 erythrocyte rosetting to deplete residual T cells. Anti-thymocyte globulin provided graft rejection prophylaxis. No additional @entity2132 ( @entity2132 ) prophylaxis was planned. Estimated disease-free survival at 4 years is 56.8% for the entire group and 75% in @entity1 with standard-risk disease. The cumulative incidence of relapse is 6%. Acute @entity2132 grade II-III developed in 9% and chronic @entity2132 in 29% of @entity1 . @entity281 occurred in 5 of 35 (14%) @entity1 . There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of @entity2132 . Its curative potential is reflected in the remarkably low relapse rate at 4 years.
